Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple Myeloma

August 17th 2016

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Shaji Kumar on Upfront Combination Treatments in Multiple Myeloma

August 16th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.

Dr. Michele Cavo on ASCT Role in Novel-Agent Era of Multiple Myeloma

August 12th 2016

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses the role of upfront autologous stem cell transplantation (ASCT) in multiple myeloma.

ASCT Retains Key Role in Myeloma Care

August 3rd 2016

Andrzej Jakubowiak, MD, discusses the impact of a recent cross-study comparison analysis and the continued role of autologous stem cell transplantation in treatment of patients with multiple myeloma.

Maintenance Lenalidomide May Improve Survival in Post-ASCT Myeloma

August 1st 2016

Maintenance lenalidomide following frontline treatment with high-dose melphalan and autologous stem cell transplant reduced the risk of death by 26% versus placebo or no maintenance in patients with multiple myeloma.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016

Sequencing Monoclonal Antibodies in Myeloma

July 27th 2016

Moving Beyond Medians

July 27th 2016

Novel Agents with Len-Dex in Multiple Myeloma

July 27th 2016

Goals of Therapy for Relapsed Myeloma

July 27th 2016

Treatment Goals Based on Relapse Type in Myeloma

July 27th 2016

All Myeloma Relapses Are Not the Same

July 27th 2016

Efficacy and Safety of Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Immunotherapy Rationale in Multiple Myeloma

July 27th 2016

FDA Grants Daratumumab Combos Breakthrough Designation for Myeloma

July 26th 2016

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Dr. Jakubowiak on Finding a Cure for Patients With Multiple Myeloma

July 19th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Multiple Myeloma

July 12th 2016

Daratumumab Triplet Hailed as New Standard for Advanced Myeloma

July 11th 2016

Antonio Palumbo, MD, discusses the practice-changing findings of the phase III CASTOR trial for relapsed/refractory patients and what questions remain with the 3-drug regimen.